• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?

作者信息

Verstovsek S, Silver R T, Cross N C P, Tefferi A

出版信息

Leukemia. 2006 Nov;20(11):2067. doi: 10.1038/sj.leu.2404379. Epub 2006 Aug 31.

DOI:10.1038/sj.leu.2404379
PMID:16990780
Abstract
摘要

相似文献

1
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
Leukemia. 2006 Nov;20(11):2067. doi: 10.1038/sj.leu.2404379. Epub 2006 Aug 31.
2
Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.真性红细胞增多症中骨髓JAK2V617F等位基因负荷及其临床相关性
Leukemia. 2007 Sep;21(9):2074-5. doi: 10.1038/sj.leu.2404724. Epub 2007 May 3.
3
Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.真性红细胞增多症患者中JAK2V617F的鉴定与真性红细胞增多症的传统诊断标准高度相关。
Am J Hematol. 2007 Jan;82(1):80-2. doi: 10.1002/ajh.20721.
4
Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera.JAK2V617F突变在鉴别真性红细胞增多症与特发性红细胞增多症中的应用价值。
Leuk Res. 2007 Jan;31(1):97-101. doi: 10.1016/j.leukres.2006.02.027. Epub 2006 Apr 18.
5
[Correlations of JAK2V617F point mutation with clinical and laboratory features in patients with polycythemia vera].真性红细胞增多症患者JAK2V617F点突变与临床及实验室特征的相关性
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):121-4.
6
Concurrent JAK2(V617F) mutation and MTHFR(C677T) homozygosity in an adolescent with polycythemia vera: case report and discussion.
Clin Pediatr (Phila). 2013 Jul;52(7):671-4. doi: 10.1177/0009922812447280. Epub 2012 May 23.
7
Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.JAK2V617F阴性真性红细胞增多症中JAK2外显子12突变的患病率及临床病理相关性
Leukemia. 2007 Sep;21(9):1960-3. doi: 10.1038/sj.leu.2404810. Epub 2007 Jun 28.
8
Mutation screening for JAK2V617F: when to order the test and how to interpret the results.JAK2V617F的突变筛查：何时进行检测以及如何解读结果。
Leuk Res. 2006 Jun;30(6):739-44. doi: 10.1016/j.leukres.2006.01.004. Epub 2006 Feb 7.
9
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera.在一名真性红细胞增多症患者中，除检测到JAK2 V617F突变外，还发现了一种新的JAK2 D620E突变。
Leukemia. 2006 Dec;20(12):2210-1. doi: 10.1038/sj.leu.2404419. Epub 2006 Sep 28.
10
JAK2 Mutations are present in all cases of polycythemia vera.真性红细胞增多症的所有病例中均存在JAK2突变。
Leukemia. 2008 Jun;22(6):1289. doi: 10.1038/sj.leu.2405047. Epub 2007 Dec 13.

引用本文的文献

1
Domain affiliated distilled knowledge transfer for improved convergence of Ph-negative MPN identifier.用于改善 Ph 阴性 MPN 标识符收敛的领域关联蒸馏知识转移。
PLoS One. 2024 Sep 27;19(9):e0303541. doi: 10.1371/journal.pone.0303541. eCollection 2024.
2
Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk.不定向潜能造血与动脉粥样血栓形成风险。
Thromb Haemost. 2022 Sep;122(9):1435-1442. doi: 10.1055/a-1830-2147. Epub 2022 Apr 20.
3
JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F- MPNs.
JAK2S523L，一种在JAK2V617F-骨髓增殖性肿瘤关键自调控残基上的新型功能获得性突变。
Blood Adv. 2020 Sep 22;4(18):4554-4559. doi: 10.1182/bloodadvances.2019001283.
4
Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study.液滴数字PCR在骨髓增殖性肿瘤等位基因突变负担评估中优于实时定量PCR：一项回顾性研究
Diagnostics (Basel). 2020 Mar 5;10(3):143. doi: 10.3390/diagnostics10030143.
5
Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.韩国真性红细胞增多症和原发性血小板增多症患者的遗传特征
J Clin Lab Anal. 2016 Nov;30(6):1061-1070. doi: 10.1002/jcla.21981. Epub 2016 May 2.
6
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms.诊断BCR/ABL阴性慢性骨髓增殖性肿瘤的分子方法。
Rev Bras Hematol Hemoter. 2011;33(4):290-6. doi: 10.5581/1516-8484.20110079.
7
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.骨髓增殖性肿瘤中的表观遗传学异常：新型治疗策略的靶点。
Clin Epigenetics. 2011 Aug;2(2):197-212. doi: 10.1007/s13148-011-0050-6. Epub 2011 Jul 9.
8
Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera.用于检测真性红细胞增多症 JAK2 V617F 突变的无标记探针熔解曲线分析的开发和实验室间验证。
PLoS One. 2011;6(10):e26534. doi: 10.1371/journal.pone.0026534. Epub 2011 Oct 20.
9
JAK2 V617F and the evolving paradigm of polycythemia vera.JAK2 V617F与真性红细胞增多症不断演变的范式
Korean J Hematol. 2010 Jun;45(2):90-4. doi: 10.5045/kjh.2010.45.2.90. Epub 2010 Jun 30.
10
Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.根据 2008 年世界卫生组织标准进行的骨髓增殖性肿瘤的分类和诊断。
Int J Hematol. 2010 Mar;91(2):174-9. doi: 10.1007/s12185-010-0529-5. Epub 2010 Feb 27.